Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03197870 · ClinicalTrials.gov registry record · Phase 2
The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
A Phase 2 study, sponsored by EyePoint Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 167
- Enrollment target
NCT03197870 is a Phase 2 study that has completed, run by EyePoint Pharmaceuticals. The registered enrollment target is 167 participants.
The verdict
NCT03197870, a Phase 2 study, has completed, sponsored by EyePoint Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 167 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of subcutaneously administered AKB-9778 15mg once daily or 15mg twice daily for 12 months in patients with moderate to severe non-proliferative diabetic retinopathy (NPDR).
Interventions
- DRUG Placebo
- DRUG AKB-9778
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2017-06-09 |
| Est. Completion | 2019-02-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03197870
The ClinicalTrials.gov registry entry for NCT03197870 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 167 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EyePoint Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03197870 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03197870 about?
NCT03197870 is a clinical study titled "The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)". The purpose of this study is to evaluate the safety and efficacy of subcutaneously administered AKB-9778 15mg once daily or 15mg twice daily for 12 months in patients with moderate to severe non-proliferative diabetic retinopathy (NPDR).
What is the current status of trial NCT03197870?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 167 participants. The study started on 2017-06-09. Estimated completion is 2019-02-09.
What interventions are being tested in trial NCT03197870?
The interventions under investigation include: Placebo (DRUG), AKB-9778 (DRUG).
Who is sponsoring clinical trial NCT03197870?
This trial is sponsored by EyePoint Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.